How strongly blood sugar, hunger, satiety, and weight change depends, among other things, on the dose, duration of treatment, lifestyle, and individual metabolic situation
Overall gastrointestinal adverse event rates Across the STEP trials, 72.9% of participants receiving semaglutide 2.4 mg reported at least one gastrointestinal adverse event, compared to 47.1% on placebo
Three peptides = three quality-control variables
For more insights, explore this comprehensive guide on what to expect when taking tirzepatide
Differential characteristics in drug-induced autoimmune hepatitis
The study revealed that HbA1c reductions were consistent across all age groups, indicating that age may not significantly influence the glycemic response to semaglutide treatment